Abstract:Our previous studies have indicated that myoepithelial cells surrounding ductal and acinar epithelium of glandular organs, such as the breast, exert multiple paracrine suppressive effects on incipient and developing cancers that arise from this epithelium. Myoepithelial cells and derived cell lines (HMS 1–6) exert these effects through the secretion of a number of different effector molecules that exert anti-invasive, anti-proliferative, and anti-angiogenic activities. Since previous basic and clinical studies have examined the role of estrogen agonists and antagonists on human breast cancer cells and because issues of hormone replacement therapy (HRT) and tamoxifen chemoprevention are such timely issues in breast cancer, we wondered whether or not hormonal manipulations might affect myoepithelial cells in vitro as far as their paracrine suppressive activities on breast cancer were concerned. The present in vitro study demonstrates that treatment of myoepithelial cells with tamoxifen but not 17β-estradiol increases both maspin secretion and invasion-blocking ability. Furthermore tamoxifen but not 17β-estradiol increases inducible nitric oxide synthase (iNOS) expression and nitric oxide (NO) production by myoepithelial cells when they are co-cultured with conditioned media from or breast carcinoma cells directly. This increased myoepithelial NO exerts both autocrine and paracrine antiproliferative effects which can be blocked by inhibition of iNOS. 17β-Estradiol, however, competes with all of these suppressive effects of tamoxifen suggesting that the mechanism of tamoxifen action is estrogen receptor mediated. Myoepithelial cells lack ER-α but express ER-β. Tamoxifen, but not 17β-estradiol, increases AP-1 CAT but not ERE-CAT activity. Again, 17β-estradiol competes with the transcription-activating effects of tamoxifen. These experiments collectively suggest that the actions of tamoxifen on the increased secretion of maspin and increased production of NO by myoepithelial cells are mediated through ER-β and the transcription-activation of an ER-dependent AP-1 response element.

Tamoxifen Stimulates Human Papillomavirus Type 16 Gene Expression and Cell Proliferation in a Cervical Cancer Cell Line.

Effects of Human Papillomavirus Type 16 E7 Protein on the Growth of Cervical Carcinoma Cells and Immuno-Escape Through the TGF-β1 Signaling Pathway

[Effect of Evn-50 on Cell Growth and Apoptosis in Tamoxifen-Resistance Human Breast Cancer Cell Line MCF-7/TAM-R].

Novel Tumor-Promoting Property of Tamoxifen

Effects of Estradiol and Tamoxifen on Proliferation of Human Breast Cancer Cells and Human Endometrial Cells.

Transcriptome Sequencing Profiles of Cervical Cancer Tissues and SiHa Cells

Tamoxifen Enhances Myoepithelial Cell Suppression of Human Breast Carcinoma Progression in Vitro by Two Different Effector Mechanisms

Identification of differentially expressed genes in human breast cancer cells induced by 4-hydroxyltamoxifen and elucidation of their pathophysiological relevance and mechanisms

The G protein-coupled receptor GPR30 mediates the proliferative and invasive effects induced by hydroxytamoxifen in endometrial cancer cells.

Regulation of cell growth and human papillomavirus 18 E7 expression by estrogen in cervical carcinoma cells

Tamoxifen activates Nrf2-dependent SQSTM1 transcription to promote endometrial hyperplasia.

Sex Hormones Are Weak Regulators of HPV16 DNA-immortalized Human Uterine Exocervical Epithelial Cells.

Human Papillomavirus E7 Oncoprotein Promotes Proliferation and Migration Through the Transcription Factor E2F1 in Cervical Cancer Cells

Mir-2861 Acts As a Tumor Suppressor Via Targeting EGFR/AKT2/CCND1 Pathway in Cervical Cancer Induced by Human Papillomavirus Virus 16 E6

A Transcriptomic Landscape of Human Papillomavirus 16 E6‐regulated Gene Expression and Splicing Events

Transcriptional Gene Silencing of HPV16 E6/E7 Induces Growth Inhibition Via Apoptosis in Vitro and in Vivo

Sensitization To Tamoxifen By Tanshinone Iia In Tamoxifen-Resistant Breast Cancer Cells In Vitro

17β-Estradiol, Genistein, and 4-Hydroxytamoxifen Induce the Proliferation of Thyroid Cancer Cells through the G Protein-Coupled Receptor GPR30

The effect of estrogen and tamoxifen on the growth of endometrial carcinoma cell

Hypomethylation Associated Enhanced Transcription of Trefoil Factor-3 Mediates Tamoxifen-Stimulated Oncogenicity of ER+ Endometrial Carcinoma Cells

Dose-dependent effect of tamoxifen in tamoxifen-resistant breast cancer cells via stimulation by the ERK1/2 and AKT signaling pathways.